
- Ipsen’s second-quarter sales reported at EUR 901.0 million, slightly above the estimated EUR 894.4 million.
- Oncology revenue reached EUR 633.0 million, exceeding the estimate of EUR 623.4 million.
- Neuroscience revenue was EUR 184.9 million, which is below the estimated EUR 190.9 million.
- Revenue from rare diseases stood at EUR 83.1 million.
- Ipsen has upgraded its financial guidance for the fiscal year 2025:
- Total sales are expected to grow by more than 7.0% at constant exchange rates, compared to the previous guidance of over 5.0%.
- The core operating margin is projected to be greater than 32.0% of total sales, up from the previous guidance of greater than 30%.
- CEO David Loew highlighted strong momentum in Ipsen’s half-year results, particularly in the rapidly growing rare liver disease franchise.
- The current market sentiment includes 7 buys, 9 holds, and 1 sell recommendation for Ipsen’s stock.
A look at Ipsen SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investment analysts are closely monitoring Ipsen SA, a company that specializes in manufacturing and selling medical drugs for various diseases like oncology and endocrinology. The company has received a mixed bag of Smart Scores, with a Value score of 3, indicating moderate value, and a Dividend score of 2, suggesting a lower dividend potential. On the bright side, Ipsen SA has scored a solid 4 on Resilience, indicating a strong ability to weather market fluctuations. Growth and Momentum scores stand at 3 each, showing promising signs in these areas. Overall, there seems to be a cautious optimism among analysts regarding Ipsen SA‘s long-term prospects.
With a diverse portfolio in targeted disease areas, Ipsen SA continues to attract attention from investors and analysts alike. While the Smart Scores paint a varied picture for the company, highlighting areas of strength like resilience, there are also areas like dividends where improvement could be sought. Despite this, the Growth and Momentum scores present a balanced view of potential growth opportunities for Ipsen SA in the future. As the company navigates the complex healthcare landscape, analysts are keenly observing how Ipsen SA‘s strategic decisions and market positioning will play out in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars